Search Results

Displaying Results 9551-9575 of 20913 "'R'"

Strengthen Readiness for a Potential SAS-to-<em>R</em> Shift in Data Analytics, Upcoming Webinar Hosted by Xtalks

Apr 29, 2026, 08:30 ET Strengthen Readiness for a Potential SAS-to-R Shift in Data Analytics, Upcoming Webinar Hosted by Xtalks

In this free webinar, see how R can support a compliant, future-ready approach to clinical data analytics. Attendees will learn about governance and validation strategies for R in GxP environments. The featured speakers will share organizational considerations when transitioning analytic platforms.

More news about: Xtalks

Apr 29, 2026, 08:30 ET WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

worldwide.With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient,

More news about: WuXi Biologics

Apr 29, 2026, 08:30 ET Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update

recognized as a non-cash expense.Research and Development Expenses increased to $20.1 million, from $6.2 million in 2024. The increase in R&D expense was primarily attributable to investment in product advancement, including both new hardware and software-based technologies and enhancements

More news about: BDMD

Apr 29, 2026, 08:29 ET Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

https://rarediseases.org/rare-diseases/whim-syndrome/. Accessed April 20263. Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35-454.

More news about: Norgine B.V.

Apr 29, 2026, 08:22 ET Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

More news about: Norgine B.V.

Apr 29, 2026, 08:10 ET Applications Now Open for Second Annual Blueberry Boost Accelerator, Seeking Next Generation of Blueberry Innovation

commercialize what's next, now by turning startup innovation into measurable business growth. Through their 'Build. Buy. Partner.' approach, they accelerate R&D, de-risk M&A, and rapidly validate new technologies in-market. VentureFuel helps organizations with end-to-end innovation engines that deliver

More news about: U.S. Highbush Blueberry Council

Apr 29, 2026, 08:07 ET J.S. Held Leads Ongoing Global Wind-Down of Katerra, Inc., One of the Largest Construction Bankruptcies on Record

/PRNewswire/ -- As the Katerra, Inc., Chapter 11 proceedings reach a milestone phase, global consulting firm J.S. Held, along with Plan Administrator Daniel R. Williams, CPA, CTP, shares an update on the wind-down of the multi-billion-dollar construction company. Katerra's 2021 bankruptcy filing stands as one

More news about: J.S. Held

Apr 29, 2026, 08:00 ET United Imaging Healthcare Releases 2025 Annual Report and Q1 2026 Results, Delivering Strong Growth with Accelerated Global Expansion

2025, United Imaging Healthcare continued to deepen its commitment to innovation, with annual R&D investment reaching RMB 2.62 billion, up 15.95% year-on-year. Leveraging sustained high-intensity R&D investment and its globally coordinated innovation network, the Company made significant progress

More news about: United Imaging Healthcare Co., Ltd.

Apr 29, 2026, 08:00 ET Citius Oncology Ships First International Order of LYMPHIR™ to Europe

diftitox‑cxdl)INDICATIONLYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.IMPORTANT SAFETY INFORMATION BOXED WARNING:

More news about: Citius Oncology, Inc.

Apr 29, 2026, 08:00 ET nT-Tao and Israel's National Water Company Mekorot Partner to Explore Fusion Energy for Critical Water Infrastructure

Agreement establishes a framework to supply clean, continuous power to critical water infrastructure and a dedicated R&D pilot facility TEL AVIV, Israel, April 29, 2026 /PRNewswire/ --

More news about: nT-Tao

Apr 29, 2026, 08:00 ET Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus

More news about: Acurx Pharmaceuticals, Inc.

Apr 29, 2026, 08:00 ET Toyota Hydrogen Solutions Achieves Key Certifications for Commercial Fuel Cell Units

commercialization and business operations of Toyota's hydrogen fuel cell technologies. Based in Gardena, California, H2HQ works collaboratively with Toyota's R&D offices in Michigan and Texas, as well as business units in Japan and internationally, to create zero-emissions fuel cell technologies that enable

More news about: Toyota Motor North America

Apr 29, 2026, 08:00 ET Research Solutions' Scite Launches Claude Connector For Citation-Backed Research

RSSS).About Research SolutionsResearch Solutions, Inc. (NASDAQ: RSSS) is a holding Company providing software and AI solutions for enterprise R&D teams and academic institutions. Through proprietary data, integrated workflows, and access infrastructure, the Company gives modern researchers and

More news about: Research Solutions, Inc.

KING'S HAWAIIAN AND VAN LEEUWEN JOIN FORCES TO LAUNCH FIRST-OF-ITS-KIND UBE COCONUT ICE CREAM AND ICE CREAM SANDWICH TO CELEBRATE NATIONWIDE LAUNCH OF UBE COCONUT SWEET ROLLS

Apr 29, 2026, 08:00 ET KING'S HAWAIIAN AND VAN LEEUWEN JOIN FORCES TO LAUNCH FIRST-OF-ITS-KIND UBE COCONUT ICE CREAM AND ICE CREAM SANDWICH TO CELEBRATE NATIONWIDE LAUNCH OF UBE COCONUT SWEET ROLLS

kingshawaiian.com/ube and vanleeuwenicecream.com to learn more.About King's HawaiianFounded 75 years ago in Hilo, Hawaii, by Robert R. Taira, KING'S HAWAIIAN is a family-owned business that has been dedicated to providing Hawaii-inspired foods made with original recipes and Aloha Spirit

More news about: King's Hawaiian

Apr 29, 2026, 07:55 ET ITALY AND SWITZERLAND: AN ALLIANCE FOR RESEARCH

Research Center and then, since 1997, with this site in Plan-les-Ouates, one of our largest production facilities. It is precisely the proximity of the R&D and production units—which we recently expanded based on criteria of efficiency and quality with an investment of over 80 million euros—that is an

More news about: Bracco SpA

Apr 29, 2026, 07:52 ET L'ITALIE ET LA SUISSE : UNE ALLIANCE AU SERVICE DE LA RECHERCHE

Centre de recherche, puis, depuis 1997, sur ce site de Plan-les-Ouates, l'une de nos plus grandes usines. C'est précisément la proximité des unités de R&D et de production, que nous avons récemment agrandies selon des critères d'efficacité et de qualité grâce à un investissement de plus de 80 millions

More news about: Bracco SpA

Apr 29, 2026, 07:47 ET AbbVie Reports First-Quarter 2026 Financial Results

adjusted SG&A expense was 22.7 percent of net revenues. On a GAAP basis, research and development (R&D) expense was 16.5 percent of net revenues. The adjusted R&D expense was 15.1 percent of net revenues. Acquired IPR&D and milestones expense was 5.0 percent

More news about: AbbVie

Apr 29, 2026, 07:13 ET Flex LNG - Invitation to the 2026 First Quarter Presentation

https://news.cision.com/flex-lng/r/flex-lng---invitation-to-the-2026-first-quarter-presentation,c4342197

More news about: Flex LNG

Apr 29, 2026, 07:00 ET Daqo New Energy Announces Unaudited First Quarter 2026 Financial Results

expensesResearch and development (R&D) expenses were $0.8 million, compared to $0.7 million in the fourth quarter of 2025 and $0.5 million in the first quarter of 2025. R&D expenses can vary from period to period and reflect R&D activities that take place during the quarter.Loss

More news about: Daqo New Energy Corp.

Apr 29, 2026, 06:59 ET Dana Incorporated Reports Strong First-Quarter Results; Maintains Full-Year Guidance; Announces New Business Win

"Dana's long-term strategy is clear and built on actions fully within our control – improving our cost structure and executing with discipline" said R. Bruce McDonald, Chairman and Chief Executive Officer. "Our first-quarter results demonstrate our progress with meaningful margin expansion and continued

More news about: Dana Incorporated

Apr 29, 2026, 06:30 ET Entergy reports first quarter 2026 financial results

Total Parent debt (R)=(G+O+P+Q)7,063

More news about: Entergy Corporation

Apr 29, 2026, 06:30 ET PROSPERITY BANCSHARES, INC.® REPORTS FIRST QUARTER 2026 EARNINGS

(R)

More news about: Prosperity Bancshares, Inc.

Apr 29, 2026, 06:14 ET JCET, 2026년 1분기 주주 귀속 순이익 전년 대비 42.7% 급증 보고

사업 구조 최적화를 가속화하고 연중 실질적인 성장의 기반을 마련했다.역량 확장과 병행하여 JCET는 핵심 기술 영역에서 연구개발 인프라와 엔지니어링 역량을 지속적으로 강화하고 있다. 상하이의 JCET 장장 연구개발 빌딩(JCET Zhangjiang R&D Building)은 1분기에 공식 운영을 시작했다. 전용 칩 성능 실험실을 포함한 최첨단 시설을 갖춘 새로운 센터는 기술적 돌파구, 제품 검증 및 최고급 엔지니어링 인재 개발을 위한 강력한 지원을 제공한다.JCET 그룹의 리정(Li Zheng) 최고경영자는

More news about: JCET Group

Apr 29, 2026, 06:11 ET JCET、2026年第1四半期の親会社株主に帰属する純利益が前年同期比42.7％増

スの国際顧客向けに新製品の導入を成功させ、事業構造の最適化を加速し、年間を通じた大幅な成長への道を切り開きました。能力増強と並行して、JCETは中核技術分野における研究開発インフラとエンジニアリング能力の強化を続けています。第1四半期には、上海のJCET Zhangjiang R&D Buildingが正式に操業を開始しました。専用のチップ性能研究所を含む最新鋭の設備を備えた新センターは、技術的ブレークスルー、製品検証、トップクラスのエンジニアリング人材の育成を強力にサポートします。JCET Group CEOのLi Zheng氏は次のように述べています。「